Clinical TrialJun 9, 2026, 07:02 AM
Invivyd Doses First Participants in LIBERTY Phase 3 Trial for VYD2311
AI Summary
Invivyd, Inc. announced that the first participants have been dosed in the LIBERTY Phase 3 clinical trial for VYD2311, its investigational monoclonal antibody for COVID-19 prevention. The randomized, double-blind study will evaluate the comparative safety, tolerability, and immunology of VYD2311 alone, an mRNA COVID-19 vaccine alone, and VYD2311 co-administered with a vaccine in healthy adults. Invivyd expects to report topline data from LIBERTY in Q3 2026, coinciding with data from the pivotal DECLARATION trial, as part of its broader REVOLUTION clinical program aimed at establishing VYD2311 as a preferred COVID-19 prevention option.
Key Highlights
- Invivyd dosed first participants in the LIBERTY Phase 3 clinical trial for VYD2311.
- LIBERTY evaluates VYD2311 alone, mRNA COVID-19 vaccine alone, and co-administration.
- Primary endpoints focus on safety, including adverse events and injection site reactions.
- The trial is expected to enroll approximately 210 adult participants aged 18 to 49 years.
- Topline data from the LIBERTY trial are anticipated in Q3 2026.
- LIBERTY is part of Invivyd's REVOLUTION clinical program for COVID-19 prevention.
- VYD2311 is a novel monoclonal antibody candidate for COVID-19 prophylaxis.
Price Impact
More from IVVD